Ilt3 ligand
AssigneeMerck Sharp & Dohme Corp.
InventorsDaniel Cua, Holly Cherwinski, Adele Wang, Yi Chen, Barbara Joyce-Shaikh
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
Claims15
(canceled)
An antibody or antigen-binding fragment thereof comprising:
- (i) a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:
- 10;
- CDR2 comprising the amino acid sequence of SEQ ID NO:
- 11;
- CDR3 comprising the amino acid sequence of SEQ ID NO:12;
- and a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:13;
- CDR2 comprising the amino acid sequence of SEQ ID NO:14;
- CDR3 comprising the amino acid sequence of SEQ ID NO:15;
- or
- (ii) a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:18;
- CDR2 comprising the amino acid sequence of SEQ ID NO:19;
- CDR3 comprising the amino acid sequence of SEQ ID NO:20;
- and a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:21;
- CDR2 comprising the amino acid sequence of SEQ ID NO:22;
- CDR3 comprising the amino acid sequence of SEQ ID NO:23;
- or
- (iii) a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:26;
- CDR2 comprising the amino acid sequence of SEQ ID NO:27;
- CDR3 comprising the amino acid sequence of SEQ ID NO:28;
- and a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:29;
- CDR2 comprising the amino acid sequence of SEQ ID NO:30;
- CDR3 comprising the amino acid sequence of SEQ ID NO:31;
- or
- (iv) a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:34;
- CDR2 comprising the amino acid sequence of SEQ ID NO:35;
- CDR3 comprising the amino acid sequence of SEQ ID NO:36;
- and
- a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:37;
- CDR2 comprising the amino acid sequence of SEQ ID NO:38;
- CDR3 comprising the amino acid sequence of SEQ ID NO:39.
-8. (canceled)
A complex between ILT3 and ILT3 ligand wherein the ILT3 ligand is PI16.
11-20. (canceled)
A method for determining whether a substance agonizes or antagonizes binding between ILT3 and ILT3 ligand, the method comprising:
- contacting ILT3 ligand with ILT3 in the presence of the substance and determining whether the ILT3 ligand and the ILT3 form a complex;
- wherein the substance is determined to agonize said binding if more of the complex is determined in the presence of the substance than in the absence of the substance and wherein the substance is determined to antagonize said binding if less of the complex is determined in the presence of the substance than in the absence of the substance, wherein the ILT3 ligand is PI16.
(canceled)
Dependencies are inferred from the claim text.